New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:40 EDTCYTRCytRx reports additional analyses supporting results from Phase 2 trial
CytRx reported positive results from additional statistical analyses that further support the previously announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas. Additional analysis determined hazard ratios for the primary endpoint of progression-free survival by both investigators at study sites and by a blinded radiology review performed at an independent central laboratory. The hazard ratio for investigator-read scans is 0.37, reflecting a 63% reduction in the risk of disease progression; and the hazard ratio for central lab scans is 0.59, reflecting a 41% reduction in the risk of disease progression. Hazard ratios – the likelihood that the study endpoint will be reached during a given period – are an important measure of the reliability and uniformity of the absolute data for PFS, as presented below. Hazard ratios where the upper limit is less than 1 indicate that there is a significant difference between the two study groups. CytRx also reported that a Kaplan-Meier analysis of the trial results, which describes the time it takes for tumors to progress in individual patients, showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin. CytRx expects to present full study results for this clinical trial at the American Society for Clinical Oncology Meeting in June, 2014 in Chicago, Illinois.
News For CYTR From The Last 14 Days
Check below for free stories on CYTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
07:19 EDTCYTRCytRx presents aldoxorubicin Phase 2b trial data
CytRx announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin has been selected for oral presentation at the 2014 American Society for Clinical Oncology Annual Meeting. Aldoxorubicin is currently being studied in a pivotal, global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma and HIV-related Kaposi’s sarcoma.
April 11, 2014
10:35 EDTCYTRHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use